HomeCompareBSX vs CPB

BSX vs CPB: Dividend Comparison 2026

BSX yields 3.18% · CPB yields 7.03%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPB wins by $21.8K in total portfolio value
10 years
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →
CPB
CPB
● Live price
7.03%
Share price
$22.18
Annual div
$1.56
5Y div CAGR
9.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.0K
Annual income
$3,333.04
Full CPB calculator →

Portfolio growth — BSX vs CPB

📍 CPB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSXCPB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSX + CPB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSX pays
CPB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
CPB
Annual income on $10K today (after 15% tax)
$597.84/yr
After 10yr DRIP, annual income (after tax)
$2,833.08/yr
At 15% tax rate, CPB beats the other by $2,832.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSX + CPB for your $10,000?

BSX: 50%CPB: 50%
100% CPB50/50100% BSX
Portfolio after 10yr
$31.1K
Annual income
$1,666.68/yr
Blended yield
5.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
CPB
Analyst Ratings
4
Buy
15
Hold
9
Sell
Consensus: Hold
Price Target
$29.20
+31.7% upside vs current
Range: $23.00 — $38.00
Altman Z
1.7
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSX buys
6
CPB buys
0
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSXCPB
Forward yield3.18%7.03%
Annual dividend / share$2.00$1.56
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%9.2%
Portfolio after 10y$20.2K$42.0K
Annual income after 10y$0.32$3,333.04
Total dividends collected$321.00$17.7K
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Staples
Analyst consensusBuyHold
Analyst price target$108.35$29.20

Year-by-year: BSX vs CPB ($10,000, DRIP)

YearBSX PortfolioBSX Income/yrCPB PortfolioCPB Income/yrGap
1← crossover$10,859$158.91$11,468$768.04$609.00CPB
2$11,700$80.63$13,170$898.91$1.5KCPB
3$12,559$40.60$15,145$1,053.51$2.6KCPB
4$13,459$20.36$17,442$1,236.44$4.0KCPB
5$14,411$10.20$20,116$1,453.22$5.7KCPB
6$15,425$5.10$23,234$1,710.48$7.8KCPB
7$16,507$2.55$26,877$2,016.28$10.4KCPB
8$17,664$1.28$31,139$2,380.35$13.5KCPB
9$18,901$0.64$36,133$2,814.49$17.2KCPB
10$20,225$0.32$41,995$3,333.04$21.8KCPB

BSX vs CPB: Complete Analysis 2026

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →

CPBConsumer Staples

Campbell Soup Company, together with its subsidiaries, manufactures and markets food and beverage products the United States and internationally. The company operates through Meals & Beverages and Snacks segments. The Meals & Beverages segment engages in the retail and foodservice businesses in the United States and Canada. This segment provides Campbell's condensed and ready-to-serve soups; Swanson broth and stocks; Pacific Foods broth, soups, and non-dairy beverages; Prego pasta sauces; Pace Mexican sauces; Campbell's gravies, pasta, beans, and dinner sauces; Swanson canned poultry; Plum baby food and snacks; V8 juices and beverages; and Campbell's tomato juice. The Snacks segment retails Pepperidge Farm cookies, crackers, fresh bakery, and frozen products; Milano cookies and Goldfish crackers; and Snyder's of Hanover pretzels, Lance sandwich crackers, Cape Cod and Kettle Brand potato chips, Late July snacks, Snack Factory Pretzel Crisps, Pop Secret popcorn, Emerald nuts, and other snacking products. This segment is also involved in the retail business in Latin America. It sells its products through retail food chains, mass discounters and merchandisers, club stores, convenience stores, drug stores, and dollar stores, as well as e-commerce and other retail, commercial, and non-commercial establishments, and independent contractor distributors. The company was founded in 1869 and is headquartered in Camden, New Jersey.

Full CPB Calculator →
📬

Get this BSX vs CPB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSX vs SCHDBSX vs JEPIBSX vs OBSX vs KOBSX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.